MAIA Biotechnology, Inc. , a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase ...

The Biotechnology Program has also expanded its STEM outreach efforts to include a summer internship program for high school ...

Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark ...

NEW YORK, May 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX ) , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...

The poster, titled “Outer Retina-Choroid en ... Ophthalmology of MERIT. About the Presentation: • Title: “Outer Retina-Choroid en face Image, ORC™: Characterization of A Novel Morphologic ...

About Gain Therapeutics, Inc. Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug ...

BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and ...

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt Disease type 1 (STGD1) and ...

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering ... today announced that the company will present three posters related to both of its pipeline programs at the ...

dose limiting toxicity dose level has not been identified in doses up to 250 mg/day Preclinical posters strengthen the NXP900 clinical development strategy as single agent in biomarker-targeted ...

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that the company will present ...